Evaluation and Management of CKD
By:
Daphne Harrington Knicely Division of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, Virginia

Search for other papers by Daphne Harrington Knicely in
Current site
Google Scholar
PubMed Close
and
Sumeska Thavarajah Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Search for other papers by Sumeska Thavarajah in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 23: Issue 4
Published Online:
Oct 2024
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand
Cover Nephrology Self-Assessment Program
Copyright:
Copyright © 2024 by the American Society of Nephrology 2024
Page Count:
13
Article Category:
Research Article
Print Publication Date:
01 Oct 2024
Published Online:
Oct 2024
  • 1.

    Stauffer ME, Fan T: Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE 9: e84943, 2014 PubMed

  • 2.

    Kim YH, et al.: The estimated mediating roles of anemia-related variables in the association between kidney function and mortality: A National Health and Nutrition Examination Survey (NHANES) study. Scientific Reports 14: 6621, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Hanna RM, Streja E, Kalantar-Zadeh K: Burden of anemia in chronic kidney disease: Beyond erythropoietin. Adv Ther 38: 52–75, 2021 PubMed

  • 4.

    Macdougall IC: Anaemia in CKD-treatment standard. Nephrol Dial Transplant 39: 770–777, 2024 PubMed

  • 5.

    Palaka E, Grandy S, van Haalen H, McEwan P, Darlington O: The impact of CKD anaemia on patients: Incidence, risk factors, and clinical outcomes—A systematic literature review. Int J Nephrol 2020: 7692376, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Hoshino J, Muenz D, Zee J, Sukul N, Speyer E, Guedes M, CKDopps Investigators, et al.: Associations of hemoglobin levels with health-related quality of life, physical activity, and clinical outcomes in persons with stage 3–5 nondialysis CKD. J Ren Nutr 30: 404–414, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Hain D, Bednarski D, Cahill M, Dix A, Foote B, Haras MS, et al.: Iron-deficiency anemia in CKD: A narrative review for the kidney care team. Kidney Med 5: 100677, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Wittbrodt ET, James G, Kumar S, van Haalen H, Chen H, Sloand JA, et al.: Contemporary outcomes of anemia in US patients with chronic kidney disease. Clin Kidney J 15: 244–252, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Covic A, Nistor I, Donciu M-D, Dumea R, Bolignano D, Goldsmith D, et al.: Erythropoiesis-stimulating agents (ESA) for preventing the progression of chronic kidney disease: A meta-analysis of 19 studies. Am J Nephrol 40: 263–279, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Elliott S, Tomita D, Endre Z: Erythropoiesis stimulating agents and reno-protection: A meta-analysis. BMC Nephrol 18: 14, 2017 PubMed

  • 11.

    KDIGO: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Inter Suppl 2: 279–335, 2012

  • 12.

    Awan AA, Walther CP, Richardson PA, Shah M, Winkelmayer WC, Navaneethan SD, et al.: Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. Nephrol Dial Transplant 36: 129–136, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Bazeley JW, Wish JB: Recent and emerging therapies for iron deficiency in anemia of CKD: A review. Am J Kidney Dis 79: 868–876, 2022 PubMed

  • 14.

    Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: An updated systematic review and meta-analysis. Am J Kidney Dis 68: 677–690, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    National Institute for Health and Care Excellence: Chronic kidney disease: Assessment and management; NICE guideline (NG203). Available at https://www.nice.org.uk/guidance/ng203. Accessed June 4, 2024.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, et al.: Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol 18: 345, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Babitt JL, Eisenga MF, Haase VH, Kshirsagar AV, Levin A, Locatelli F, Conference Participants, et al.: Controversies in optimal anemia management: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) conference. Kidney Int 99: 1280–1295, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, PIVOTAL Investigators and Committees, et al.: Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380: 447–458, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Portolés J, Martín L, Broseta JJ, Cases A: Anemia in chronic kidney disease: From pathophysiology and current treatments, to future agents. Front Med (Lausanne) 8: 642296, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Chung EY, Palmer SC, Saglimbene VM, Craig JC, Tonelli M, Strippoli GF, et al.: Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: A network meta-analysis. Cochrane Database Syst Rev 2: CD010590, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Hahn D, Esezobor CI, Elserafy N, Webster AC, Hodson EM: Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients. Cochrane Database Syst Rev 1: CD011690, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Sakaguchi Y, Hamano T, Wada A, Masakane I: Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol 30: 1037–1048, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Minutolo R, Garofalo C, Chiodini P, Aucella F, Del Vecchio L, Locatelli F, et al.: Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease. Nephrol Dial Transplant 36: 267–274, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Stoumpos S, Crowe K, Sarafidis P, Barratt J, Bolignano D, Del Vecchio L, et al.: Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: A document by the European Renal Best Practice board of the European Renal Association [published online ahead of print Apr 4, 2024]. Nephrol Dial Transplant doi:10.1093/ndt/gfae0752024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Agrawal D, Varade D, Shah H, Nazar A, Krishnan J, Shukla V, Study Investigator Group, et al.: Desidustat in anemia due to non-dialysis-dependent chronic kidney disease: A phase 3 study (DREAM-ND). Am J Nephrol 53: 352–360, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T, et al.: Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: A randomized, open-label, phase 3 study. Am J Nephrol 52: 884–893, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Akizawa T, Nangaku M, Yamaguchi T, Koretomo R, Maeda K, Miyazawa Y, et al.: A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: The SYMPHONY ND study. Kidney Int Rep 6: 1840–1849, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T, et al.: Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: A randomized, phase 3 trial. Am J Nephrol 52: 871–883, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Nangaku M, Kondo K, Kokado Y, Ueta K, Kaneko G, Tandai T, et al.: Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. J Am Soc Nephrol 32: 1779–1790, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Chertow GM, Pergola PE, Farag YMK, Agarwal R, Arnold S, Bako G, PRO2TECT Study Group, et al.: Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med 384: 1589–1600, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Nangaku M, Hamano T, Akizawa T, Tsubakihara Y, Nagai R, Okuda N, et al.: Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: A 52-week randomized open-label phase 3 trial. Am J Nephrol 52: 26–35, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, ASCEND-ND Study Group, et al.: Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med 385: 2313–2324, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Akizawa T, Iwasaki M, Otsuka T, Yamaguchi Y, Reusch M: Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney Int Rep 6: 1810–1828, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Barratt J, Andric B, Tataradze A, Schömig M, Reusch M, Valluri U, et al.: Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant 36: 1616–1628, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Fatima K, Ahmed W, Fatimi AS, Mahmud O, Mahar MU, Ali A, et al.: Evaluating the safety and efficacy of daprodustat for anemia of chronic kidney disease: A meta-analysis of randomized clinical trials. Eur J Clin Pharmacol 78: 1867–1875, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Coyne DW, Roger SD, Shin SK, Kim SG, Cadena AA, Moustafa MA, et al.: Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep 6: 624–635, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, et al.: Roxadustat for treating anemia in patients with CKD not on dialysis: Results from a randomized phase 3 study. J Am Soc Nephrol 32: 737–755, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Shutov E, Sułowicz W, Esposito C, Tataradze A, Andric B, Reusch M, et al.: Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: A phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant 36: 1629–1639, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, et al.: Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med 381: 1001–1010, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Johansen KL, Cobitz AR, Singh AK, Macdougall IC, Lopes RD, Obrador GT, et al.: The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease. Kidney Int 103: 1180–1192, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Provenzano R, Szczech L, Leong R, Saikali KG, Zhong M, Lee TT, et al.: Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: Pooled results of three randomized clinical trials. Clin J Am Soc Nephrol 16: 1190–1200, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, et al.: Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 8: CD013751, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Abdelazeem B, Shehata J, Abbas KS, El-Shahat NA, Malik B, Savarapu P, et al.: The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials. PLoS One 17: e0266243, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Minutolo R, Liberti ME, Simeon V, Sasso FC, Borrelli S, De Nicola L, et al.: Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: Meta-analysis of phase 3 randomized controlled trials. Clin Kidney J 17: sfad143, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Singh AK, McCausland FR, Claggett BL, Wanner C, Wiecek A, Atkins MB, et al.: Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrol Dial Transplant 38: 1890–1897, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Nangaku M, Akizawa T, Nagakubo T, Yonekawa T, Kimura T, Endo Y, et al.: Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan. Ther Apher Dial 26: 1065–1078, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Zheng Q, Wang Y, Yang H, Sun L, Zhang P, Zhang X, et al.: Cardiac and kidney adverse effects of HIF prolyl-hydroxylase inhibitors for anemia in patients with CKD not receiving dialysis: A systematic review and meta-analysis. Am J Kidney Dis 81: 434–445.e1, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, et al.: Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol 7: 1234–1241, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Sinnathamby ES, Banh KT, Barham WT, Hernandez TD, De Witt AJ, Wenger DM, et al.: Hyperkalemia: Pharmacotherapies and clinical considerations. Cureus 16: e52994, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105: S117–S314, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Palmer BF, Clegg DJ: Hyperkalemia treatment standard. Nephrol Dial Transplant 39: 1097–1104, 2024 PubMed

  • 52.

    Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero J-J, Chan W, et al.: KDOQI clinical practice guideline for nutrition in CKD: 2020 update. Am J Kidney Dis 76: S1–S107, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Clase CM, Carrero J-J, Ellison DH, Grams ME, Hemmelgarn BR, Jardine MJ, Conference Participants, et al.: Potassium homeostasis and management of dyskalemia in kidney diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int 97: 42–61, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    MacLaughlin HL, McAuley E, Fry J, Pacheco E, Moran N, Morgan K, et al.: Re-thinking hyperkalaemia management in chronic kidney disease—Beyond food tables and nutrition myths: An evidence-based practice review. Nutrients 16: 3, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Zarantonello D, Brunori G: The role of plant-based diets in preventing and mitigating chronic kidney disease: More light than shadows. J Clin Med 12: 6137, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Naismith DJ, Braschi A: An investigation into the bioaccessibility of potassium in unprocessed fruits and vegetables. Int J Food Sci Nutr 59: 438–450, 2008 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Picard K: Potassium additives and bioavailability: Are we missing something in hyperkalemia management? J Ren Nutr 29: 350–353, 2019 PubMed

  • 58.

    Cupisti A, Kovesdy C, D’Alessandro C, Kalantar-Zadeh K: Dietary approach to recurrent or chronic hyperkalaemia in patients with decreased kidney function. Nutrients 10: 261, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Palmer BF, Colbert G, Clegg DJ: Potassium homeostasis, chronic kidney disease, and the plant-enriched diets. Kidney360 1: 65–71, 2020 PubMed

  • 60.

    Clegg DJ, Headley SA, Germain MJ: Impact of dietary potassium restrictions in CKD on clinical outcomes: Benefits of a plant-based diet. Kidney Med 2: 476–487, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Kessler C, Ng J, Valdez K, Xie H, Geiger B: The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. J Hosp Med 6: 136–140, 2011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Mistry M, Shea A, Giguère P, Nguyen M-L: Evaluation of sodium polystyrene sulfonate dosing strategies in the inpatient management of hyperkalemia. Ann Pharmacother 50: 455–462, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Gruver J, Al-Makki A, Shepler B: Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: A systematic review of randomized controlled clinical trials. J Pharm Pharm Sci 26: 11892, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Pitt B, Bushinsky DA, Kitzman DW, Ruschitzka F, Metra M, Filippatos G, Patiromer-204 Investigators, et al.: Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Fail 5: 257–266, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Costa D, Patella G, Provenzano M, Ielapi N, Faga T, Zicarelli M, et al.: Hyperkalemia in CKD: An overview of available therapeutic strategies. Front Med (Lausanne) 10: 1178140, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Desai NR, Rowan CG, Alvarez PJ, Fogli J, Toto RD: Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization. PLoS One 15: e0226844, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, et al.: Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 372: 222–231, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Ash SR, Batlle D, Kendrick J, Oluwatosin Y, Pottorf W, Brahmbhatt Y, et al.: Effect of sodium zirconium cyclosilicate on serum potassium and bicarbonate in patients with hyperkalemia and metabolic acidosis associated with chronic kidney disease: Rationale and design of the NEUTRALIZE study. Nephron 146: 599–609, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Dong L, Xu W, Deng Y, Tan J, Qin W: Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia. Eur J Pharmacol 931: 175174, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Adamczak M, Surma S: Metabolic acidosis in patients with CKD: Epidemiology, pathogenesis, and treatment. Kidney Dis (Basel) 7: 452–467, 2021 PubMed

  • 71.

    Skiba K, Gojowy D, Szotowska M, Bartmańska M, Kolonko A, Cierpka L, et al.: Metabolic acidosis in kidney transplant recipients. Pol Arch Intern Med 128: 587–593, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Melamed ML, Raphael KL: Metabolic acidosis in CKD: A review of recent findings. Kidney Med 3: 267–277, 2021 PubMed

  • 73.

    Imenez Silva PH, Unwin R, Hoorn EJ, Ortiz A, Trepiccione F, Nielsen R, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target), et al.: Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease. Nephrol Dial Transplant 37[Suppl 2]: ii4–ii12, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Bellocq A, Suberville S, Philippe C, Bertrand F, Perez J, Fouqueray B, et al.: Low environmental pH is responsible for the induction of nitric-oxide synthase in macrophages. Evidence for involvement of nuclear factor-κB activation. J Biol Chem 273: 5086–5092, 1998 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Kopple JD, Kalantar-Zadeh K, Mehrotra R: Risks of chronic metabolic acidosis in patients with chronic kidney disease. Kidney Int Suppl: S21–S27, 2005 PubMed

  • 76.

    Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB: Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients? Nephrology (Carlton) 11: 394–399, 2006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Dobre M, Pajewski NM, Beddhu S, Chonchol M, Hostetter TH, Li P, SPRINT Research Group, et al.: Serum bicarbonate and cardiovascular events in hypertensive adults: Results from the Systolic Blood Pressure Intervention Trial. Nephrol Dial Transplant 35: 1377–1384, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Carrero JJ, González-Ortiz A, Avesani CM, Bakker SJL, Bellizzi V, Chauveau P, et al.: Plant-based diets to manage the risks and complications of chronic kidney disease. Nat Rev Nephrol 16: 525–542, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Navaneethan SD, Shao J, Buysse J, Bushinsky DA: Effects of treatment of metabolic acidosis in CKD: A systematic review and meta-analysis. Clin J Am Soc Nephrol 14: 1011–1020, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Goraya N, Simoni J, Jo C-H, Wesson DE: A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate. Clin J Am Soc Nephrol 8: 371–381, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Noce A, Marrone G, Wilson Jones G, Di Lauro M, Pietroboni Zaitseva A, Ramadori L, et al.: Nutritional approaches for the management of metabolic acidosis in chronic kidney disease. Nutrients 13: 2534, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Sorohan BM, Obrișcă B, Jurubiță R, Lupușoru G, Achim C, Andronesi A, et al.: Sodium citrate versus sodium bicarbonate for metabolic acidosis in patients with chronic kidney disease: A randomized controlled trial. Medicine (Baltimore) 103: e37475, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Di Iorio BR, Bellasi A, Raphael KL, Santoro D, Aucella F, Garofano L, The UBI Study Group, et al.: Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: The UBI study. J Nephrol 32: 989–1001, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Hultin S, Hood C, Campbell KL, Toussaint ND, Johnson DW, Badve SV, et al.: A systematic review and meta-analysis on effects of bicarbonate therapy on kidney outcomes. Kidney Int Rep 6: 695–705, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al.: 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol 72: 879–895, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Juraschek SP, Kovell LC, Miller ER, Gelber AC: Association of kidney disease with prevalent gout in the United States in 1988–1994 and 2007–2010. Semin Arthritis Rheum 42: 551–561, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Zhu Y, Pandya BJ, Choi HK: Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 63: 3136–3141, 2011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Krishnan E: Reduced glomerular function and prevalence of gout: NHANES 2009 Reduced glomerular function and prevalence of gout: NHANES 2009–10. PLoS One 7: e50046, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Sampson AL, Singer RF, Walters GD: Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev 10: CD009460, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237–241, 2006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Sellmayr M, Petzsche MRH, Ma Q, Krüger Q, Liapis H, Brink A, et al., Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease. J Am Soc Nephrol 31: 2773–2792, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Johnson RJ, Sanchez Lozada LG, Lanaspa MA, Piani F, Borghi C: Uric acid and chronic kidney disease: Still more to do. Kidney Int Rep 8: 229–239, 2023 PubMed

  • 93.

    Kocaman SA, Sahinarslan A, Cemri M, Timurkaynak T, Boyaci B, Cengel A, et al.: Independent relationship of serum uric acid levels with leukocytes and coronary atherosclerotic burden. Nutr Metab Cardiovasc Dis 19: 729–735, 2009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, CKD-FIX Study Investigators, et al.: Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med 382: 2504–2513, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, FEATHER Study Investigators, et al.: Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: A randomized trial. Am J Kidney Dis 72: 798–810, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al.: 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76: 29–42, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Sutton Burke EM, Kelly TC, Shoales LA, Nagel AK: Angiotensin receptor blockers effect on serum uric acid—A class effect? J Pharm Pract 33: 874–881, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Suijk DLS, van Baar MJB, van Bommel EJM, Iqbal Z, Krebber MM, Vallon V, et al.: SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function. Clin J Am Soc Nephrol 17: 663–671, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Khanna PP, Khanna D, Cutter G, Foster J, Melnick J, Jaafar S, et al.: Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: A phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 73: 1523–1532, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Huddleston EM, Gaffo AL: Emerging strategies for treating gout. Curr Opin Pharmacol 65: 102241, 2022 PubMed

  • 101.

    Saag KG, Khanna PP, Keenan RT, Ohlman S, Osterling Koskinen L, Sparve E, et al.: A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares. Arthritis Rheumatol 73: 1533–1542, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Davison SN, Koncicki H, Brennan F: Pain in chronic kidney disease: A scoping review. Semin Dial 27: 188–204, 2014 PubMed

  • 103.

    Weisbord SD, Mor MK, Sevick MA, Shields AM, Rollman BL, Palevsky PM, et al.: Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis. Clin J Am Soc Nephrol 9: 1594–1602, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Koncicki HM, Unruh M, Schell JO: Pain management in CKD: A guide for nephrology providers. Am J Kidney Dis 69: 451–460, 2017 PubMed

  • 105.

    Koncicki HM, Brennan F, Vinen K, Davison SN: An approach to pain management in end stage renal disease: Considerations for general management and intradialytic symptoms. Semin Dial 28: 384–391, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Daubresse M, Alexander GC, Crews DC, Segev DL, McAdams-DeMarco MA: Trends in opioid prescribing among hemodialysis patients, 2007–2014. Am J Nephrol 49: 20–31, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Davison SN: Clinical pharmacology considerations in pain management in patients with advanced kidney failure. Clin J Am Soc Nephrol 14: 917–931, 2019 PubMed

  • 108.

    Kimmel PL, Fwu C-W, Abbott KC, Eggers AW, Kline PP, Eggers PW, et al.: Opioid prescription, morbidity, and mortality in United States dialysis patients. J Am Soc Nephrol 28: 3658–3670, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Roy PJ, Weltman M, Dember LM, Liebschutz J, Jhamb M, HOPE Consortium: Pain management in patients with chronic kidney disease and end-stage kidney disease. Curr Opin Nephrol Hypertens 29: 671–680, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Jhamb M, Steel JL, Yabes JG, Roumelioti M-E, Erickson S, Devaraj SM, et al.: Effects of technology assisted stepped collaborative care intervention to improve symptoms in patients undergoing hemodialysis: The TACcare randomized clinical trial. JAMA Intern Med 183: 795–805, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Inayama E, Yamada Y, Kishida M, Kitamura M, Nishino T, Ota K, et al.: Effect of music in reducing pain during hemodialysis access cannulation: A crossover randomized controlled trial. Clin J Am Soc Nephrol 17: 1337–1345, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 112.

    Barakzoy AS, Moss AH: Efficacy of the World Health Organization analgesic ladder to treat pain in end-stage renal disease. J Am Soc Nephrol 17: 3198–3203, 2006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    United States Renal Data System: 2023 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States, Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases, 2023

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Poonawalla I, Barve K, Cockrell M, Agarwal A, Casebeer AW, Dixon SW, et al.: Transition-to-dialysis planning, health care use, and mortality in end-stage renal disease. Am J Manag Care 29: 81–87, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Quinn RR, Lam NN, Ravani P, Oliver MJ, Blake PG, Tonelli M, et al.: The Advancing American Kidney Health Initiative: The challenge of measuring success. JASN 33: 1060–1062, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Green JA, Cavanaugh KL: Understanding the influence of educational attainment on kidney health and opportunities for improved care. Adv Chronic Kidney Dis 22: 24–30, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Nicoll R, Robertson L, Gemmell E, Sharma P, Black C, Marks A, et al.: Models of care for chronic kidney disease: A systematic review. Nephrology (Carlton) 23: 389–396, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    Liu J, Zhou Y, Tang Y, Chen J, Li J: Patient engagement during the transition from nondialysis-dependent chronic kidney disease to dialysis: A meta-ethnography. Health Expect 26: 2191–2204, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Rizzolo K, Shen JI: Barriers to home dialysis and kidney transplantation for socially disadvantaged individuals. Curr Opin Nephrol Hypertens 33: 26–33, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Chan CT, Collins K, Ditschman EP, Koester-Wiedemann L, Saffer TL, Wallace E, et al.: Overcoming barriers for uptake and continued use of home dialysis: An NKF-KDOQI conference report. Am J Kidney Dis 75: 926–934, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Zhang Y, Baharani J: Dialysis education and options for late presenters—An ongoing dilemma. Hemodial Int 27: 224–230, 2023 PubMed

  • 122.

    Raghavan D, Holley JL: Conservative care of the elderly CKD patient: A practical guide. Adv Chronic Kidney Dis 23: 51–56, 2016 PubMed

  • 123.

    Carson RC, Juszczak M, Davenport A, Burns A: Is maximum conservative management an equivalent treatment option to dialysis for elderly patients with significant comorbid disease? Clin J Am Soc Nephrol 4: 1611–1619, 2009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Imasawa T, Saito C, Kai H, Iseki K, Kazama JJ, Shibagaki Y, et al.: Long-term effectiveness of a primary care practice facilitation program for chronic kidney disease management: An extended follow-up of a cluster-randomized FROM-J study. Nephrol Dial Transplant 38: 158–166, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Hamroun A, Glowacki F, Frimat L: Comprehensive conservative care: What doctors say, what patients hear. Nephrol Dial Transplant 38: 2428–2443, 2023 PubMed

  • 126.

    Davison SN, Levin A, Moss AH, Jha V, Brown EA, Brennan F, Kidney Disease: Improving Global Outcomes, et al.: Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: Developing a roadmap to improving quality care. Kidney Int 88: 447–459, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 127.

    Macdougall IC, Bircher AJ, Eckardt K-U, Obrador GT, Pollock CA, Stenvinkel P, Conference Participants, et al.: Iron management in chronic kidney disease: Conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) controversies conference. Kidney Int 89: 28–39, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 128.

    Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI: Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis, and treatment. J Am Soc Nephrol 31: 456–468, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 5937 5937 1677
Full Text Views 654 654 49
PDF Downloads 824 824 63